Evidence map›Paper›PMID 24778994›Full record

ArticleTranslational medicine @ UniSa2014

Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges.

C Palladino, B Bruno, M Boccadoro

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Translational medicine @ UniSa, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

C PalladinoDivision of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino , Torino, Italy.
B BrunoDivision of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino , Torino, Italy.
M BoccadoroDivision of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino , Torino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a non malignant plasma cell disorder with a relatively low risk of progression to Multiple Myeloma (MM) and to related Plasma cells disordes (lymphoplasmacellular neoplasms, Waldenstrom Macroglobulinemia or light chain amyloidosis). It is a quite common finding, especially in the population above the age of 50 and it can also present in association with many non malignant conditions. Differential diagnosis of symptomatic and asymptomatic forms is the determinant for starting therapy. Over the last few years many advances in the understanding of the biology of MGUS, together with large epidemiological studies, allowed to define risk models to estimate the risk of progression to MM according to MGUS isotype and, more recently, to peculiar flow cytometry findings. The goal of many recent studies aims at evaluating individual patients and their overall risk of progression, the detection of early signs of progression and the development of timely treatment strategies.

Indexed as

MGUSMonoclonal gammopathy of undetrmined significancenon malignant haematological disorderspre-malignant haematological neoplasms

Identifiers

PMID24778994
PMCPMC4000459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.